MT-200605

MICOT 点击蓝字 关注我们 Slide to view different languages  滑动查看不同语言 脑梗，学名为缺血性卒中，是由于脑部动脉严重狭窄或闭塞导致局部脑组织缺血、缺氧性坏死的临床综合征。根据最新全球疾病负担数据，全球每年1200万人新发脑梗，550万人因此离世。换算下来，每不到3秒钟，世界上就有一个人遭遇脑梗。 更让人揪心的是幸存者的处境——70%至80% 的脑梗幸存者会留下不同程度的神经损伤后遗症。说话含糊不清、半边身子动不了、走路需要人搀扶、吃饭容易呛咳……这些不是极少数人的不幸，而是大多数脑梗患者要面对的现实。 很多人以为，脑梗就是血管堵了，疏通开就好了。但现实远比想象中复杂。 脑梗真正的伤害，不只是那根堵住的血管 溶栓和取栓确实是目前最主流的血管再通手段，但一个事实是：临床上，仅有9.4%的发病患者接受了静脉溶栓，意味着大部分脑梗患者在发病后没有接受溶栓治疗。 而且溶栓药物有严格的时间窗限制，通常要求在发病4.5小时内使用；取栓手术的时间窗稍长，但也大多要求在6到24小时内完成。再加上患者本人及家属对脑梗症状的识别延迟、赶到医院所需的时间、医院资质和设备等条件的限制，真正能赶在时间窗内完成血管再通的患者非常少。 这意味着，大多数脑梗患者，只能依靠常规的保守治疗——用一些抗血小板药物、控制血压血糖、营养神经，然后等待大脑自己恢复。 保守治疗不是不管用，而是太被动。它缺少一个能够主动干预脑梗后“细胞崩溃”过程的武器。这正是脑梗的致残率依然居高不下的根本原因之一。 因为脑梗真正的伤害，不只是那根堵住的血管，而是血管堵塞后大脑里那场“细胞大崩溃”。 1986年的诺贝尔奖，改写了大脑的命运 在回答“为什么血管通了人还不好”之前，我们先回到1986年的诺贝尔生理学或医学奖。 那一年，丽塔·列维-蒙塔尔奇尼和斯坦利·科恩因发现神经生长因子（NGF） 而获奖。这个发现震撼了当时的医学界——它第一次证明：神经细胞不是“一次性”的消耗品，而是可以被特定物质“滋养”和“保护”的。 在此之前，科学界普遍认为成年人的大脑就像一块用完的电池，神经元死一个少一个，永远无法再生。但NGF的发现撕开了这道裂口：原来，神经元像植物一样，需要特定的“养分”才能存活、生长和维持功能。 神经生长因子的发现，是现代神经保护研究的奠基石。 它开启了一个全新的时代——科学家们开始相信，如果能找到大脑自带的“生长密码”，就有可能在脑部遭受重创（比如脑梗）时，用药物给濒死的神经元提供营养，保住它们。 基于这一逻辑，科学家们进一步发现了大脑中类似NGF的更多“滋养因子”，其中最关键的，叫做脑源性神经营养因子（BDNF） 。它就是大脑自带的“修复总指挥”。 脑梗后，大脑里倒塌的“四块多米诺骨牌” 有了诺贝尔奖的铺垫，我们现在可以理解：脑梗的本质，是大脑的“养分供应站”被切断了。 血管堵塞后，脑组织断氧断糖，那些依赖能量生存的神经元开始像多米诺骨牌一样连环崩塌。 第一块牌 断电缺氧，细胞开始“闹饥荒” 血管堵死后几分钟，堵塞区域的神经细胞能量工厂（线粒体）停工。维持细胞内外平衡的“离子泵”失灵，钙离子大量涌入细胞内，激活了各种破坏性酶，细胞从内部被啃噬。 第二块牌 兴奋性毒性，细胞被“激动死” 缺氧状态下，神经细胞会大量释放一种叫做“谷氨酸”的兴奋性递质。它像失控的洪水一样淹没周围的神经细胞，过度刺激它们，把它们“激动”致死。你可以想象：被困在火灾现场的人，不是被火烧死，而是被身边同样被困的人拼命摇晃致死——这就是兴奋性毒性。 第三块牌 血流再通，反而带来二次打击 医生紧急开通血管是绝对的救命措施，但反直觉的是，血流恢复也会带来伤害。突然涌入的氧气在受损的线粒体中产生大量氧自由基，像火星死灰复燃，对已经极度脆弱的脑组织发起新一轮攻击——这就是再灌注损伤。 第四块牌 炎症风暴，大脑“自我凋亡” 损伤信号激活大脑自身的免疫细胞，引发剧烈炎症。炎症因子破坏保护大脑的“血脑屏障”，加剧水肿，并强行启动神经细胞的“自我凋亡程序”。 这一系列连环反应，集中在缺血半暗带——梗死核心周围“半死不活”的区域。如果能及时干预，这片区域还能救；如果放任，损伤将不可逆转。 传统治疗为什么不够？ 溶栓和取栓疏通了堵塞的血管，解决了“水管不通”的问题，这是卒中治疗伟大的进步。但它们瞄准的是“水管”，却无法保护田里受损的“庄稼”（缺血半暗带神经元）。 过去几十年，科学家尝试了各种神经保护药，试图作为“铲除火灾的消防员”堵住某一个破坏性环节，比如单纯清除氧自由基。但脑梗是连环性的级联反应，仅解决单一环节就像派一个消防员去扑灭一整座燃烧的城市，往往力不从心。 更关键的是，很多旧策略忽略了诺贝尔奖级别的核心逻辑：不仅要防止神经细胞死掉，还要滋养受损的神经细胞去“生长”，让它自己修复。 如果没有“养分”滋养，即使细胞暂时活下来，它也是失能的、萎缩的，无法重建神经网络——这就是为什么很多患者血管通了，仍长期受偏瘫、失语等后遗症困扰。 新思路：向诺贝尔奖致敬——一边“护”，一边“修” 如果我们把NGF/BDNF这类神经营养因子看作大脑自带的“修复总指挥”，那么理想中的脑梗药物，不仅要做铲除火灾的消防员，还要做下达修复指令的总指挥。 但这里有一个巨大的挑战：血脑屏障。这是大脑的一道天然“城墙”，用来阻挡血液中的有害物质进入脑组织。但也正因为这道屏障，绝大多数药物无法进入大脑发挥作用——这也是过去很多神经保护药物在实验室有效、到临床上却失败的重要因素。 由麦科医药自主研发的MT200605，是一款能够高效穿透血脑屏障的小分子静脉注射液。这意味着它能真正“抵达战场”，在脑组织内部直接发挥作用。而且，在目前所有进入临床阶段的缺血性卒中治疗药物中，MT200605是唯一能够穿透血脑屏障、靶向BDNF/TrkB通路、具有神经营养作用的小分子激动剂。这一独特性，让它有望填补“神经营养修复”这一领域的临床空白。 基于这一前提，MT200605设计了双机制协同的治疗思路： 主动“护”——扑灭“大火”，减少伤亡 精准清除梗死后及再灌注后产生的大量氧自由基，同时抑制神经细胞凋亡、减轻炎症风暴，为濒死的神经元争取“黄金抢救时间”。这叫主动保护——先稳住局面，及时止损。 主动“修”——重启大脑的自愈力 这正是MT200605向诺贝尔奖成果致敬的核心设计。它穿越血脑屏障，选择性激活大脑里TrkB受体——这个受体，正是大脑自带的“养分”（BDNF）所作用的靶点。通过激活TrkB，MT200605相当于直接下达了BDNF的修复指令，告诉受损的神经细胞：“活下来，然后长出新的连接！” 这叫主动修复——它不是替代大脑工作，而是激活大脑神经细胞自身的再生潜能，促进神经突触重塑，为长期功能恢复铺路。 MT200605的作用机制（来源：麦科医药招股书） 一边灭火，一边重建；一边防止死亡，一边下达“生长”的指令。 这就是MT200605与以往脑神经保护药物的本质区别——它既尊重了诺贝尔奖揭示的“神经营养”真理，又直面了脑梗后复杂的病理战场。 让更多脑梗患者，活得有尊严 脑梗后遗症有多残酷？70%到80%的幸存者深有体会——曾经能自己吃饭、走路、说话的人，一夜之间连一个字都说不清楚，连端起一杯水都做不到。 而中国每年新增409万例脑梗——这意味着数百万个家庭被拖入漫长的照护泥潭。发病后的前3个月是神经功能恢复的黄金窗口。如果在这段时间里，除了开通血管之外，还有一种药物能同时做到“阻止神经细胞死亡”和“重启大脑自愈力”，那将意味着什么？ 意味着更多的人可以摆脱卧床状态，重新实现生活自理、体面独立；意味着许多家庭不必困在无休止的长期照护之中；意味着脑梗之后，人生不必被永久的残疾定义。 MT200605已完成了涉及360例患者的II期临床研究数据库锁定，即将进入揭盲和统计分析阶段。创新药研发道路漫长，但从1986年诺贝尔奖为神经保护埋下种子，到今天“护修并举”的药物走进临床验证，科学的每一步都在回应同一个问题：人的尊严，能不能在脑梗之后被保住？ 创新药研发道路漫长，但每一次扎实的推进，都让希望更近一步。 MICOT Ischemic stroke, or cerebral infarction, is caused by severe stenosis or occlusion of a cerebral artery, leading to focal cerebral ischemia, hypoxia, and tissue necrosis. According to the latest Global Burden of Disease data, 12 million people worldwide experience a new ischemic stroke each year, and 5.5 million die from it—equivalent to one new case less than every three seconds. Among survivors, 70%–80% are left with neurological deficits of varying severity, including slurred speech, unilateral weakness or paralysis, impaired mobility, and choking or coughing while eating. These are not rare outcomes, but the reality faced by most survivors. Many people assume that reopening the blocked vessel solves the problem. The reality is far more complex. The Damage Goes Beyond the Blocked Vessel IV thrombolysis and mechanical thrombectomy are the main recanalization therapies. However, only 9.4% of patients receive IV thrombolysis, meaning that most do not receive thrombolytic treatment after stroke onset. Thrombolytic drugs generally must be given within 4.5 hours of onset. Mechanical thrombectomy has a longer window, usually 6–24 hours. Delayed symptom recognition, travel time, and limitations in hospital capabilities and equipment mean that few patients receive recanalization within the treatment window. Most patients therefore receive standard medical management, including antiplatelet therapy, blood pressure and glucose control, and neurotrophic support, while waiting for the brain to recover. Such treatment is not ineffective, but remains passive. It cannot actively interrupt the cellular injury cascade after ischemic stroke, which is one reason post-stroke disability remains high. The damage lies not only in the blocked vessel, but also in the cellular collapse that follows. How the 1986 Nobel Prize Changed Our Understanding of the Brain To understand why patients may not recover after blood flow is restored, we need to return to the 1986 Nobel Prize in Physiology or Medicine. Rita Levi-Montalcini and Stanley Cohen received the prize for discovering growth factors—nerve growth factor (NGF) and epidermal growth factor (EGF), respectively. Their discoveries showed that nerve cells can be supported and protected by specific biological factors. Previously, the adult brain was widely viewed as a depleted battery: once a neuron died, it was permanently lost. NGF challenged this belief by showing that neurons require specific trophic signals to survive, grow, and maintain function. The discovery of NGF laid the foundation for modern neuroprotection. It suggested that drugs might preserve endangered neurons by harnessing the brain’s intrinsic growth signals after severe injury, including ischemic stroke. Scientists later identified additional neurotrophic factors, including brain-derived neurotrophic factor (BDNF), a key regulator of neuronal survival and repair. The Four Dominoes After Ischemic Stroke Ischemic stroke cuts off the brain’s oxygen and glucose supply, causing energy-dependent neurons to fail in a cascade. Domino One Energy Failure Within minutes of vascular occlusion, neuronal mitochondria stop functioning. Ion pumps fail, calcium enters the cells, and destructive enzymes damage them from within. Domino Two Excitotoxicity Hypoxic neurons release excessive glutamate, overstimulating nearby neurons and causing cell death. This process is known as excitotoxicity. Domino Three Reperfusion Injury Emergency recanalization is lifesaving, but restored blood flow may also cause secondary injury. The sudden influx of oxygen generates reactive oxygen species (ROS) in damaged mitochondria, further attacking vulnerable brain tissue. Domino Four Neuroinflammation Damage signals activate the brain’s immune cells and trigger neuroinflammation. Inflammatory mediators disrupt the blood–brain barrier (BBB), worsen cerebral edema, and activate neuronal apoptosis. The main battleground is the ischemic penumbra—the impaired but potentially salvageable tissue surrounding the infarct core. Timely intervention may rescue it; without treatment, the damage becomes irreversible. Why Are Existing Treatments Not Enough? IV thrombolysis and mechanical thrombectomy reopen blocked vessels, a major advance in stroke treatment. However, they target the vessel and cannot directly protect vulnerable neurons in the ischemic penumbra. Over recent decades, many neuroprotective agents have targeted individual steps in the ischemic cascade, such as ROS scavenging. Yet ischemic injury is interconnected, and targeting only one step is often insufficient. More importantly, preventing neuronal death is not enough. Damaged neurons also need trophic support to survive, recover, and rebuild. Without such support, surviving neurons may remain dysfunctional and atrophic, unable to reconstruct neural networks. This may explain why many patients continue to experience hemiplegia, aphasia, and other sequelae after successful recanalization. A New Strategy: Protect and Repair If NGF and BDNF are the brain’s intrinsic repair signals, an ideal ischemic stroke therapy should both limit acute injury and initiate repair. A major challenge is the BBB. While it protects the brain from harmful substances, it also prevents most drugs from reaching brain tissue. This is one reason many neuroprotective agents that worked in laboratory studies later failed clinically. MT200605, independently developed by Micot Pharma, is a small-molecule IV formulation capable of efficiently crossing the BBB and acting directly within brain tissue. Among ischemic stroke therapies currently in clinical development, MT200605 is the only small-molecule agonist that crosses the BBB, targets the BDNF/TrkB pathway, and exerts neurotrophic effects. It may therefore address the unmet need for neurotrophic repair. MT200605 was designed with two complementary, synergistic mechanisms: Active Protection—Limiting Acute Injury MT200605 scavenges ROS generated after cerebral infarction and reperfusion, while inhibiting neuronal apoptosis and reducing inflammation, thereby providing endangered neurons with a critical therapeutic window. This is active protection: stabilizing the situation and limiting further damage. Active Repair—Reactivating Intrinsic Recovery After crossing the BBB, MT200605 selectively activates TrkB, the receptor through which BDNF exerts its effects. By activating TrkB, MT200605 delivers a BDNF-like repair signal to damaged neurons, promoting survival and the formation of new connections. This is active repair. Rather than replacing brain function, MT200605 is designed to activate neuronal regenerative potential, promote synaptic remodeling, and support long-term functional recovery. Mechanism of Action of MT200605 Source: Micot Pharma Prospectus Protecting while repairing; preventing death while promoting growth. This is the key difference between MT200605 and earlier neuroprotective agents: it combines neurotrophic support with intervention across the complex pathology of ischemic stroke. Helping More Patients Live with Dignity Seventy to eighty percent of ischemic stroke survivors experience lasting deficits. A person once able to eat, walk, and speak independently may suddenly be unable to speak clearly or lift a glass of water. China records 4.09 million new ischemic stroke cases each year, placing millions of families under prolonged caregiving pressure. The first three months after onset are a critical window for neurological recovery. During this period, what would it mean if a drug could both prevent neuronal death and reactivate the brain’s intrinsic recovery capacity, in addition to reopening the vessel? It could mean that more patients regain independence and live with dignity; that fewer families remain trapped in long-term caregiving; and that life after ischemic stroke is not permanently defined by disability. Database lock has been completed for the 360-patient Phase II clinical study of MT200605, which will soon proceed to unblinding and statistical analysis. Innovative drug development is a long journey. From the scientific foundations established by the 1986 Nobel Prize to the clinical evaluation of a therapy combining protection and repair, each step addresses the same question: Can human dignity be preserved after ischemic stroke? Every rigorous step forward brings that hope closer. MICOT